NasdaqGM - Delayed Quote • USD
ANI Pharmaceuticals, Inc. (ANIP)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 0.99 | 1.08 | 4.48 | 5.01 |
| Low Estimate | 0.88 | 1.01 | 4.29 | 4.53 |
| High Estimate | 1.08 | 1.15 | 4.66 | 5.39 |
| Year Ago EPS | 1.17 | 1.28 | 4.71 | 4.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 125.52M | 131.08M | 534.68M | 575.55M |
| Low Estimate | 122.12M | 128M | 529.6M | 561.91M |
| High Estimate | 130.09M | 133.92M | 540.8M | 585M |
| Year Ago Sales | 83.49M | 116.55M | 486.82M | 534.68M |
| Sales Growth (year/est) | 50.30% | 12.50% | 9.80% | 7.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.35 | 0.68 | 0.84 | 0.85 |
| EPS Actual | 1.17 | 1.28 | 1.27 | 1 |
| Difference | 0.82 | 0.6 | 0.43 | 0.15 |
| Surprise % | 234.30% | 88.20% | 51.20% | 17.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.99 | 1.08 | 4.48 | 5.01 |
| 7 Days Ago | 0.98 | 1.07 | 4.47 | 5.04 |
| 30 Days Ago | 0.98 | 1.07 | 4.47 | 5.04 |
| 60 Days Ago | 1.03 | 1.08 | 4.33 | 5.01 |
| 90 Days Ago | 0.98 | 1.06 | 4.21 | 4.91 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | ANIP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -15.40% | -- | -- | 1.50% |
| Next Qtr. | -15.60% | -- | -- | 11.40% |
| Current Year | -4.90% | -- | -- | 5.20% |
| Next Year | 11.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 2.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -8.35% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Guggenheim: Buy to Buy | 4/23/2024 |
| Initiated | Capital One: Overweight | 3/15/2024 |
| Maintains | Guggenheim: Buy to Buy | 3/5/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/4/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/1/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/16/2024 |
Related Tickers
COLL Collegium Pharmaceutical, Inc.
35.48
-1.28%
CRDL Cardiol Therapeutics Inc.
1.7600
-4.35%
AMRX Amneal Pharmaceuticals, Inc.
6.05
+12.04%
ETON Eton Pharmaceuticals, Inc.
3.2100
-2.13%
ALKS Alkermes plc
24.65
+1.61%
IRWD Ironwood Pharmaceuticals, Inc.
8.10
-2.53%
SUPN Supernus Pharmaceuticals, Inc.
30.26
+1.04%
EGRX Eagle Pharmaceuticals, Inc.
4.5500
-4.61%
PETQ PetIQ, Inc.
16.53
-0.42%
PAHC Phibro Animal Health Corporation
12.56
-7.71%